Detalhe da pesquisa
1.
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.
Invest New Drugs
; 40(2): 314-321, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735674
2.
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
Invest New Drugs
; 39(6): 1633-1640, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34287772
3.
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
Invest New Drugs
; 39(5): 1375-1382, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33856599
4.
Systemic Administration of Pegylated Arginase-1 Attenuates the Progression of Diabetic Retinopathy.
Cells
; 11(18)2022 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139465
5.
Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.
Acta Oncol
; 51(4): 557-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22129360
6.
Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma.
Curr Cancer Drug Targets
; 12(9): 1233-43, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22873218
7.
Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis.
Pigment Cell Melanoma Res
; 24(2): 366-76, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21029397
8.
Synchronous primary lung cancer and epidermal growth factor receptor mutation.
Ann Thorac Surg
; 90(3): e38-9, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20732474